Switch View
© EQS Newswire
18.09.2025
ISIN: CH0478634105
Aevis Victoria SA
AEVS
LISTED
SIX
AEVIS VICTORIA SA – Starker Umsatzanstieg im ersten Halbjahr 2025. Der freie Cashflow übersteigt CHF 100 Millionen und ermöglicht einen Schuldenabbau von über CHF 120 Millionen.
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR
Freiburg, 18. September 2025
AEVIS VICTORIA SA (AEVS.SW) – Starker Umsatzanstieg im ersten Halbjahr 2025.Der freie Cashflow übersteigt CHF 100 Millionen und ermöglicht einen Schuldenabbau von über CHF 120 Millionen.
Die zwei operativen Sparten der Beteiligungsgesellschaft AEVIS VICTORIA SA (AEVIS) haben ihre M......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.09.2025
ISIN: CH0478634105
Aevis Victoria SA
AEVS
LISTED
SIX
AEVIS VICTORIA SA – Strong growth in revenue in the first half of 2025. Free cash flow exceeds CHF 100 million, enabling debt reduction of more than CHF 120 million.
News Preview
Ad hoc announcement pursuant to Art. 53 LR
Fribourg, 18 September 2025
AEVIS VICTORIA SA (AEVS.SW) – Strong growth in revenue in the first half of 2025.
Free cash flow exceeds CHF 100 million, enabling debt reduction of more than CHF 120 million.
The two operating divisions of the investment company AEVIS VICTORIA SA (AEVIS) strengthened the......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.09.2025
ISIN: US04537Y1091
Aspira Women's Health Inc.
AWH
LISTED
NASDAQ
Aspira Women's Health Announces Equity Capital Infusion of $3.06 Million in Private Placement and Warrant Exercise
News Preview
$2.95 Million PIPE$112 thousand warrant exercise AUSTIN, TX / ACCESS Newswire / September 18, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostics and disease management tools, today announced that it h...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
18.09.2025
ISIN: CH1335392721
Galderma Group AG
GALD
LISTED
XWSX
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay
News Preview
Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of ag...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESSWIRE
18.09.2025
ISIN: CA98980M1095
Zomedica Corporation
ZOM
LISTED
XASE
Zomedica Expands TRUVIEW(R) and TRUFORMA(R) Intellectual Property Portfolio with Four Newly Issued U.S. Patents
News Preview
Intellectual property portfolio now includes 228 Patents and 153 Trademarks providing robust protection for the Company's product platforms in the rapidly growing multi-billion dollar veterinary diagnostics market ANN ARBOR, MI / ACCESS Newswire / September 18, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: KYG4818G1010
Innovent Biologics Inc
1801
LISTED
HKSE
Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)
News Preview
SAN FRANCISCO and SUZHOU, China, Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, to...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US2825591033
89Bio, Inc.
ETNB
LISTED
NASDAQ
89bio, Inc. Announces Agreement to be Acquired by Roche
News Preview
– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash; transaction represents total equity value of up to approximately $3.5 billion –...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.09.2025
ISIN: CA69016D1087
Ovation Science Inc.
OVAT
LISTED
CSE
Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection
News Preview
VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / September 18, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC:OVATF) ("Ovation" or the "Company"), today announced an enhanced strategic partnership with Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI) ("Skinvisible") to leverage patent-pending Invisicare® topical and...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: FR0014008VX5
Euroapi S.A.
EAPI
LISTED
EURONEXT
Science Based Targets initiative (SBTi) validates EUROAPI’s near-term climate targets
News Preview
September 18, 2025 - EUROAPI’s near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi1), confirming the company’s alignment with the Paris Agreement trajectory of limiting global warming to 1.5°C above pre-industrial levels....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
News Preview
Basel, 18 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire 89bio, Inc. (Nasdaq: ETNB), a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio’s peg...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: CNE1000048G6
Remegen Co., Ltd.
9995
LISTED
HKSE
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
News Preview
YANTAI, China, Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed by RemeGen) for the treatment of generalized myasthenia gr...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: CNE1000048G6
Remegen Co., Ltd.
9995
LISTED
HKSE
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
News Preview
YANTAI, China, Sept. 18, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed by RemeGen) for the treatment of generalized myasthenia gr...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
18.09.2025
ISIN: KYG1996C1006
CARsgen Therapeutics Holdings Limited
2171
LISTED
HKSE
CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025
News Preview
SHANGHAI, Sept. 17, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the updated long-term follow-up results of Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel, R&D code: CT053, an autologous CAR T-cell product targe...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: KYG0520K1094
Ascletis Pharma Inc.
1672
LISTED
HKSE
Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
News Preview
--Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo.
--Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile. Treatment emergent adverse events (TEAEs) in the denifanstat (ASC40) group were comparable to...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: FR0000121667
EssilorLuxottica SA
EL
LISTED
EURONEXT
EssilorLuxottica: EssilorLuxottica and Meta build on their successful partnership with new AI glasses that offer a glimpse into the future
News Preview
EssilorLuxottica and Meta build on their successful partnershipwith new AI glasses that offer a glimpse into the future...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
ANRO Deadline: ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the "IPO"); and/or (ii) securities between February 2, 2024 and October 22,...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ISIN: US5324571083
Eli Lilly and Co
LLY
LISTED
NYSE
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
News Preview
In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week extension
The safety and tolerability profile of Mounjaro was generally consistent with previous adult studies
INDIANAPOLIS, Sept. 17, 2025 /PRNewswire/...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
SAN DIEGO, Sept. 17, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), have until November 10, 2025 to seek appointment as lead plaintiff of th...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US78349D1072
Rxsight Inc
RXST
LISTED
NASDAQ
EXPANDED CLASS PERIOD: Berger Montague Advises RxSight, Inc. (NASDAQ: RXST) Investors to Inquire About a Securities Fraud Class Action by September 22, 2025
News Preview
PHILADELPHIA, Sept. 17, 2025 /PRNewswire/ -- Berger Montague PC, a nationally recognized securities litigation law firm, is investigating potential securities law violations involving RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). A class action lawsuit was recently filed on behalf of investors who acquired RxSight securities between...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US1266501006
CVS Health Corp
CVS
LISTED
NYSE
CVS Health declares quarterly dividend
News Preview
WOONSOCKET, R.I., Sept. 17, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on November 3, 2025, to holders of record on October 23, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US09073N3008
Streamex Exchange Corp.
STEX
LISTED
NASDAQ
Streamex Corp., NASDAQ: STEX & Simplify Asset Management $10 billion USD AUM ETF Manager Announces Letter of Intent Pursuing a Strategic Partnership to Drive ETF Innovation through Integration of Tokenized Gold Yield Assets and Tokenization of Existing ET
News Preview
Partnership with Simplify Asset Management Unlocks Significant Opportunity for Demand of Streamex’s Yield-Bearing Gold Token and additional tokenization opportunities with Simplify, AUM of $10,017,260,875 as of 09/15/2025 Partnership with Simplify Asset Management Unlocks Significant Opportunity for Demand of Streamex’s Yield-Bearing Gold Token and...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US78349D1072
Rxsight Inc
RXST
LISTED
NASDAQ
RxSight, Inc. (RXST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
LOS ANGELES, Sept. 17, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST)....
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US90466Y1038
Unicycive Therapeutics, Inc.
UNCY
LISTED
NASDAQ
UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 17, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) be...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LifeMD, Inc. (LFMD) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
LOS ANGELES, Sept. 17, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD)....
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US00846U1016
Agilent Technologies Inc
A
LISTED
NYSE
Agilent Announces Cash Dividend of 24.8 Cents per Share
News Preview
Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on Oct. 22, 2025, to all shareholders of record as of the close of business on Sept. 30, 2025.
The timing and amounts of future dividends are subject to determination and approval by Agilent’s boa...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
Semler Scientific Inc. (SMLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
LOS ANGELES, Sept. 17, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Semler Scientific Inc. ("Semler" or the "Company") (NASDAQ: SMLR)....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: DK0062498333
Novo Nordisk A/S
NOVO B
LISTED
CPH
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
News Preview
Bagsværd, Denmark, Plainsboro, NJ, 17 September 2025 – Today, The New England Journal of Medicine published the results from the OASIS 4 phase 3 trial that studied the efficacy and safety of the investigational once-daily oral semaglutide 25 mg (Wegovy® in a pill*), marking a significant milestone in the company’s ambition to advance obesity care....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US2697961082
Eagle Pharmaceuticals Inc
EGRX
LISTED
NASDAQ
Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years
News Preview
WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders, which is scheduled to be held virtually on October 17, 2025 at 10:00 a.m. Eastern Time....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US09062X1037
Biogen Inc
BIIB
LISTED
NASDAQ
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
News Preview
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) to treat post-partum depression (PPD) in adults following childbirth. ZURZUVAE is a once-daily, oral, 14-day treatment which represents a novel therapeutic appr...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US04335A1051
Arvinas, Inc.
ARVN
LISTED
NASDAQ
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
News Preview
Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Deadline Approaching: Lantheus Holdings, Inc. (LNTH) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming November 10, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (the “Class Period”).
IF YOU ARE...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US9290331084
Vor Biopharma Inc.
VOR
LISTED
NASDAQ
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
News Preview
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the Phase 3 study in China evaluating telitacicept in adults with generalized myasthenia gravis, a study sponsored by Vor’s collaborat...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US2166484020
Cooper Companies Inc
COO
LISTED
NYSE
CooperCompanies Announces Expanded Share Repurchase Program
News Preview
SAN RAMON, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today its Board of Directors has approved a $1 billion increase in the Company’s share repurchase program. The share repurchase program now totals $2 billion....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US76200L3096
Rezolute, Inc.
RZLT
LISTED
NASDAQ
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
News Preview
REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US92243A2006
Vaxart Inc
VXRT
LISTED
NASDAQ
Vaxart Appoints W. Mark Watson as Lead Independent Director
News Preview
In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board’s interests with stockholders...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
NUTX Investors Have Opportunity to Lead Nutex Health Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 17, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nutex Health Inc. (NASDAQ: NUTX) between August 8, 2024 and August 14, 2025, both dates inclusive...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Deadline Alert: Savara Inc. (SVRA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”)....
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: JP3921310003
Medley, Inc.
44800
LISTED
XJPX
Jobley Expands Nonprofit Support Program in 2025
News Preview
Free hiring support now available to dental providers caring for underserved communities
BELLEVUE, Wash., Sept. 17, 2025 /PRNewswire/ -- Jobley today announced the expansion of its Nonprofit Support Program for 2025. As a hiring platform for U.S. dental and healthcare professionals operated by Medley (TSE: 4480), a Japan-based health technology g...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US09073N2018
BioSig Technologies, Inc.
BSGM
LISTED
NASDAQ
Streamex Corp., NASDAQ: STEX & Simplify Asset Management $10 billion USD AUM ETF Manager Announces Letter of Intent Pursuing a Strategic Partnership to Drive ETF Innovation through Integration of Tokenized Gold Yield Assets and Tokenization of Existing ET
News Preview
Partnership with Simplify Asset Management Unlocks Significant Opportunity for Demand of Streamex’s Yield-Bearing Gold Token and additional tokenization opportunities with Simplify, AUM of $10,017,260,875 as of 09/15/2025 Partnership with Simplify Asset Management Unlocks Significant Opportunity for Demand of Streamex’s Yield-Bearing Gold Token and...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Transaction in Own Shares
News Preview
For immediate release17 September 2025 WORLDWIDE HEALTHCARE TRUST PLC(the "Company") MARKET PURCHASE OF COMPANY'S OWN SHARES This notification is given, pursuant to the authority granted at an Annual General Meeting of the Company held on 9 July 2025 to make market purchases of the Company's own shares up to an aggregate maximum of 69,602,221...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US00404A1097
Acadia Healthcare Company Inc
ACHC
LISTED
NASDAQ
Acadia Healthcare to Participate in Jefferies 2025 Healthcare Services Conference
News Preview
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in a fireside chat at the Jefferies 2025 Healthcare Services Conference, September 29 - 30, 2025, in Nashville, Tennessee.
In connection with the conference, there will be an online webcast of the Company’s presentation available on the Company’s web...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH
17.09.2025 / 15:55 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certai......
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US1897631057
Co-Diagnostics Inc
CODX
LISTED
NASDAQ
Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
News Preview
SALT LAKE CITY, Sept. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into a securities purchase agreement with several institutional investors for the pur...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: INE0DK501011
Piramal Pharma Limited
PPLPHARMA
LISTED
BSE
Piramal Pharma Solutions erweitert seine Formulierungskapazitäten mit einer neuen Korsch XM-12 Zweischichttablettenpresse im Werk Morpeth, UK
News Preview
Diese Tablettenpresse wird dem Formulierungsentwicklungsteam der Einrichtung ein wichtiges Werkzeug für die Entwicklung von Kombinationen mit fester Dosierung und modifizierter Wirkstofffreisetzung an die Hand geben. Piramal Pharma Solutions hat robuste Schulungsprotokolle implementiert, um einen sicheren Betrieb und eine qualitativ hochwertige A...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US62856X3008
Q/C Technologies, Inc
QCLS
LISTED
NASDAQ
TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
News Preview
TNF Pharmaceuticals Inc. (Nasdaq: TNFA), (“TNF” or the “Company”) today announced that it received written notice from the Nasdaq Stock Market on September 16, 2025, confirming that the Company has regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2). To regain compliance with the Listing Rule...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US29405E2081
Enveric Biosciences, Inc.
ENVB
LISTED
NASDAQ
Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
News Preview
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series A warrants to purchase up to an ag...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US4448591028
Humana Inc
HUM
LISTED
NYSE
New Research in a New England Journal of Medicine Publication Finds Patients of Value-Based Care Organizations Have More Frequent and Consistent Primary Care Visits
News Preview
A new study published in The New England Journal of Medicine Catalyst, conducted by the Humana Healthcare Research team and Massachusetts General Hospital Attending Physician Dr. Suhas Gondi, who completed the research while a resident physician at Harvard Medical School's Brigham and Women's Hospital, finds that patients who receive care from sen...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FITÔ Study Failure Drives Shares 80% Lower -- Hagens Berman
News Preview
SAN FRANCISCO, Sept. 17, 2025 /PRNewswire/ -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease ("ILD"), did not meet its main goal...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US5324571083
Eli Lilly and Co
LLY
LISTED
NYSE
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
News Preview
For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses
Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%) vs. 11.0 lbs (5.3%) with oral semaglutide, a 73.6% relative improvement, in a key secondary endpoint
The safety and tolerability of orforglipron were...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC LEI: 5493003YBCY4W1IMJU04 NET ASSET VALUE The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for Worldwide Healthcare Trust PLC at the close of business on 16 September 2025 was 348.48p (cum income). For and on behalf of the B...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Advancing Cancer Research Brings New Hope for Patients Worldwide
News Preview
NetworkNewsWire Editorial Coverage
NEW YORK, Sept. 17, 2025 /CNW/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic toll on y...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Advancing Cancer Research Brings New Hope for Patients Worldwide
News Preview
NetworkNewsWire Editorial Coverage
NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic to...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Advancing Cancer Research Brings New Hope for Patients Worldwide
News Preview
NetworkNewsWire Editorial Coverage
NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic to...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
News Preview
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies
Icotrokinra also showed sustained skin clearance and favorable safety profile in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD study
Robust findings continue...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US04635X1028
Astria Therapeutics Inc
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the Phase 1a trial of STAR-0310, a YTE half-life extended monoclonal antibody antagonist of OX40, in healthy subjects. STAR-0310 demonstrated a best-...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US29405E2081
Enveric Biosciences, Inc.
ENVB
LISTED
NASDAQ
Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery
News Preview
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the publication of two peer-reviewed research papers describing innovative bioproduction strategies for creating therapeutic compounds...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US5747951003
Masimo Corporation
MASI
LISTED
NASDAQ
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs
News Preview
Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1
This press release...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: DK0060055861
Chemometec A/S
CHEMM
LISTED
CPH
Notice of Annual General Meeting 2025
News Preview
ANNOUNCEMENT NO. 293...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US75886F1075
Regeneron Pharmaceuticals Inc
REGN
LISTED
NASDAQ
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
News Preview
Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of semaglutide-induced loss of lean mass, while increasing fat mass loss...
Themefolio
Profiler
Peergroup
© Newsfile
17.09.2025
ISIN: CA9255401064
Vext Science, Inc.
VEXT
LISTED
CSE
Vext Secures State Approval for Portsmouth Dispensary Ownership Transfer
News Preview
Upon closing, expected by October 1, 2025, Portsmouth will become Vext's fifth fully consolidated dispensary in Ohio. The Company expects to bring additional locations online through late 2025 and early 2026, progressing toward the state's eight-store cap.Vancouver, British Columbia--(Newsfile Corp. - September 17, 2025) - Vext Science, Inc. (CSE:...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
